National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Dictionary of Cancer Terms
In English   En español
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
In English   En español

suberoylanilide hydroxamic acid (SOO-ber-oyl-AN-ih-lide hy-drok-SA-mik A-sid)

 A drug that is used to treat cutaneous T-cell lymphoma that does not get better, gets worse, or comes back during or after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Suberoylanilide hydroxamic acid is a type of histone deacetylase inhibitor. Also called SAHA, vorinostat, and Zolinza.



Previous Definitions:SU5416, SU6668, subcutaneous, subcutaneous port, subependymal
Next Definitions:subglottis, subjective improvement, submucosa, subserosa, subset analysis

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov